FBXL7 Upregulation Predicts a Poor Prognosis and Associates with a Possible Mechanism for Paclitaxel Resistance in Ovarian Cancer

Paclitaxel (PTX) is a common regimen used to treat patients with ovarian cancer. Although approximately 60% of ovarian cancer patients exhibit a pathologic complete response (pCR), approximately 40% of patients appear to be insensitive to PTX adjuvant therapy. Thus, identifying a useful biomarker to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Med
Main Authors: Chiu, Hui-Wen, Chang, Jeng-Shou, Lin, Hui-Yu, Lee, Hsun-Hua, Kuei, Chia-Hao, Lin, Che-Hsuan, Huang, Huei-Mei, Lin, Yuan-Feng
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6209951/
https://ncbi.nlm.nih.gov/pubmed/30301218
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm7100330
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados